Similar articles for PMID: 16109173

Year	Number of Results
2001	1
2002	1
2003	3
2004	4
2005	10
2006	19
2007	16
2008	25
2009	13
2010	3
2011	4
2012	3
2013	2
2014	1
2015	1
2016	2
2018	1
2024	0

1

Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.

Lowes MA, Turton JA, Krueger JG, Barnetson RS. Lowes MA, et al. BMC Dermatol. 2005 Aug 18;5:9. doi: 10.1186/1471-5945-5-9. BMC Dermatol. 2005. PMID: 16109173 Free PMC article.

2

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group. Leonardi CL, et al. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33. doi: 10.1016/j.jaad.2004.09.029. J Am Acad Dermatol. 2005. PMID: 15761420 Clinical Trial.

3

Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis.

Viguier M, Richette P, Aubin F, Beylot-Barry M, Lahfa M, Bedane C, Delesalle F, Richard-Lallemand MA, Delaporte E, Dubertret L, Bardin T, Bachelez H. Viguier M, et al. Arthritis Rheum. 2008 Jun;58(6):1796-802. doi: 10.1002/art.23507. Arthritis Rheum. 2008. PMID: 18512820 Free article.

4

Efalizumab-associated papular psoriasis.

Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N. Hassan AS, et al. Arch Dermatol. 2007 Jul;143(7):900-6. doi: 10.1001/archderm.143.7.900. Arch Dermatol. 2007. PMID: 17638735

5

Efalizumab, a reversible T-cell modulator for psoriasis.

Shear NH, Langley RG, Ho V. Shear NH, et al. J Cutan Med Surg. 2006;9 Suppl 1:4-9. doi: 10.1007/s10227-006-0101-3. J Cutan Med Surg. 2006. PMID: 16633862 Review.

6

New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.

Myers WA, Najarian D, Gottlieb AB. Myers WA, et al. J Dermatolog Treat. 2006;17(6):353-4. doi: 10.1080/09546630600967406. J Dermatolog Treat. 2006. PMID: 17853308

7

Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.

Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S. Costanzo A, et al. Dermatology. 2009;218(2):146-50. doi: 10.1159/000168086. Epub 2008 Oct 30. Dermatology. 2009. PMID: 18971577

8

Efalizumab-induced guttate psoriasis. Successful management and re-treatment.

Balato A, La Bella S, Gaudiello F, Balato N. Balato A, et al. J Dermatolog Treat. 2008;19(3):182-4. doi: 10.1080/09546630701691236. J Dermatolog Treat. 2008. PMID: 18569275

9

Infliximab in psoriasis and psoriatic arthritis.

Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Papoutsaki M, et al. BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638. BioDrugs. 2013. PMID: 23990278 Review.

10

The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.

Antoniou C, Stefanaki I, Stratigos A, Avgerinou G, Stavropoulos P, Potouridou I, Polidorou D, Moustou AE, Kosmadaki M, Katsambas AD. Antoniou C, et al. Br J Dermatol. 2007 Apr;156 Suppl 2:12-6. doi: 10.1111/j.1365-2133.2007.07764.x. Br J Dermatol. 2007. PMID: 17371318

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year